Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials

International Journal of Epidemiology

Volumn 44, Issue 1, 2015, Pages 264-277

  Saquib, Nazmus ^a   Saquib, Juliann ^a   Ioannidis, John P A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ANTIGEN; DATABASE; DISABILITY; LITERATURE REVIEW; META-ANALYSIS; MORTALITY;

ABDOMINAL AORTA ANEURYSM; ADULT DISEASE; ARTICLE; ASYMPTOMATIC DISEASE; BREAST CANCER; CANCER SCREENING; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MAMMOGRAPHY; META ANALYSIS (TOPIC); MORTALITY; MOUTH CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCULT BLOOD; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; ULTRASOUND; UTERINE CERVIX CANCER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; MASS SCREENING; META ANALYSIS; NEOPLASMS; STATISTICS AND NUMERICAL DATA;

UNITED STATES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921883323     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyu140     Document Type: Article

References (110)

1. Force USPST. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Int Med 2009;151: 716-26, W-236.
2. Hudson B, Zarifeh A, Young L, Wells JE. Patients' expectations of screening and preventive treatments. Ann Fam Med 2012;10: 495-502.
3. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1: CD004720.
4. Nelson HD, Huffman LH, Fu R, Harris EL, Force USPST. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Int Med 2005;143: 362-79.
5. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;6: CD001877.
6. Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane dDtabase Syst Rev 2003;2: CD003373.
7. Mittra I, Mishra GA, Singh S et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010;126: 976-84.
8. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103: 1541-49.
9. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg 2012;99: 1488-500.
10. Manser R, Lethaby A, Irving LB et al. Screening for lung cancer. Cochrane Database Syst Rev 2013;6: CD001991.
11. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013;130: 674-81.
12. Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of population-based screening for abdominal aortic aneurysm. J Vasc Surg 2010;52: 1103-08.
13. Lindholt JS, Juul S, Fasting H, Henneberg EW. Preliminary ten year results from a randomised single centre mass screening trial for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2006;32: 608-14.
14. Alexander FE, Anderson TJ, Brown HK et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999;353: 1903-08.
15. Bjurstam N, Bjorneld L, Warwick J et al. The Gothenburg Breast Screening Trial. Cancer 2003;97: 2387-96.
16. Lindholt JS, Sorensen J, Sogaard R, Henneberg EW. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial. Br J Surg 2010;97: 826-34.
17. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Int Med 2002;137 (5 Part 1): 305-12.
18. Thompson SG, Ashton HA, Gao L, Buxton MJ, Scott RA, Multicentre Aneurysm Screening Study G. Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. Br J Surg 2012;99: 1649-56.
19. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;22: 63-67.
20. Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Followup after 11 years - update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat 1997;45: 263-70.
21. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004;39: 846-51.
22. Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer 2000;89(Suppl 11): 2363-68.
23. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008;95: 1029-36.
24. Moss SM, Cuckle H, Evans A et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006;368: 2053-60.
25. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002;50: 840-44.
26. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Tento fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69: 349-55.
27. Tabar L, Vitak B, Chen TH et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260: 658-63.
28. Andriole GL, Crawford ED, Grubb RL III et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104: 125-32.
29. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375: 1624-33.
30. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305: 2295-303.
31. Hoff G, Grotmol T, Skovlund E, Bretthauer M, Norwegian Colorectal Cancer Prevention Study G. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338: b1846.
32. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353: 1207-10.
33. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59: 311-18.
34. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86: 44-53.
35. Norman PE, Jamrozik K, Lawrence-Brown MM et al. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 2004;329: 1259.
36. Oken MM, Hocking WG, Kvale PA et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306: 1865-73.
37. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342: d1539.
38. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366: 2345-57.
39. Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J med 2012;366: 981-90.
40. Segnan N, Armaroli P, Bonelli L et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial - SCORE. J Natl Cancer Inst 2011;103: 1310-22.
41. Chen JG, Parkin DM, Chen QG et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10: 204-09.
42. Infante M, Cavuto S, Lutman FR et al. A randomized study of lung cancer screening with spiral computed tomography: threeyear results from the DANTE trial. Am J Resp Crit Care Med 2009;180: 445-53.
43. Lindekleiv H, Lochen ML, Mathiesen EB, Njolstad I, Wilsgaard T, Schirmer H. Echocardiographic screening of the general population and long-term survival: a randomized clinical study. JAMA Int Med 2013;173: 1592-98.
44. Pastorino U, Rossi M, Rosato V et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21: 308-15.
45. Saghir Z, Dirksen A, Ashraf H et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 2012;67: 296-301.
46. Sankaranarayanan R, Esmy PO, Rajkumar R et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370: 398-406.
47. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360: 1385-94.
48. Sankaranarayanan R, Ramadas K, Thara S et al. Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India. Oral Oncol 2013;49: 314-21.
49. Shaukat A, Mongin SJ, Geisser MS et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369: 1106-14.
50. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380: 1741-48.
51. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130: 417-22.
52. Brett GZ. Earlier diagnosis and survival in lung cancer. Br Med J 1969;4: 260-62.
53. Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chron Dis 1986;39: 453-63.
54. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. Eur J Cancer Prev 2001;10: 131-37.
55. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol 2009;181: 1615-21; discussion 1621.
56. Levin ML, Tockman MS, Frost JK, Ball WC Jr. Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report. Recent results Cancer Res 1982;82: 138-46.
57. Marcus PM, Bergstralh EJ, Fagerstrom RM et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000;92: 1308-16.
58. Semiglazov VF, Moiseenko VM, Manikhas AG et al. [Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St Petersburg/WHO). Voprosy onkologii 1999;45: 265-71.
59. Thomas DB, Gao DL, Ray RM et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94: 1445-57.
60. Thompson SG, Ashton HA, Gao L, Scott RA, Multicentre Aneurysm Screening Study G. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009;338: b2307.
61. Eckstein HH, Bockler D, Flessenkamper I, Schmitz-Rixen T Debus S, Lang W. [Ultrasonographic screening for the detection of abdominal aortic aneurysms. ] Deutsches Arzteblatt international 106: 657-63.
62. Lindholt JS, Norman P. Screening for abdominal aortic aneurysm reduces overall mortality in men. A meta-analysis of the mid- and long-term effects of screening for abdominal aortic aneurysms. Eur J vasc Endovasc Surg 2008;36: 167-71.
63. Takagi H, Kawai N, Umemoto T. Abdominal aortic aneurysm: Screening reduces all cause mortality in men. BMJ 2007;335: 899.
64. Cosford PA, Leng GC. Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007;2: CD002945.
65. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T. Abdominal aortic aneurysm screening reduces mortality: metaanalyses of randomized, controlled trials. Eur J Vasc Endovasc Surg 2007;33: 132-33.
66. Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Int Med 2005;142: 203-11.
67. Lindholt JS, Norman PE. Meta-analysis of postoperative mortality after elective repair of abdominal aortic aneurysms detected by screening. Br J Surg 2011;98: 619-22.
68. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92: 1490-99.
69. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009;4: CD001877.
70. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006;4: CD001877.
71. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;1: CD001877.
72. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97: 1195-203.
73. Hackshaw A. EUSOMA review of mammography screening. Ann Oncol 2003;14: 1193-95.
74. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann INt Med 2002;137(5 Part 1): 347-60.
75. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355: 129-34.
76. Glasziou PP. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992;45: 1251-56.
77. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273: 149-54.
78. Magnus MC, Ping M, Shen MM, Bourgeois J, Magnus JH. Effectiveness of mammography screening in reducing breast cancer mortality in women aged 39-49 years: a meta-analysis. J Women's Health 2011;20: 845-52.
79. Bastardis-Zakas K, Iatrakis G, Navrozoglou I et al. Maximizing the benefits of screening mammography for women 40-49 years old. Clin Exp Obstet Gynecol 2010;37: 278-82.
80. Hendrick RE, Smith RA, Rutledge JH III, Smart CR. Benefit of screening mammography in women aged 40-49: a new metaanalysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997;22: 87-92.
81. Smart CR, Hendrick RE, Rutledge JH III, Smith RA. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials. Cancer 1995;75: 1619-26.
82. Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials 1993;Doc No 32.
83. Autier P, Hery C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 2009;27: 5919-23.
84. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91: 43437.
85. Towler B, Irwig L, Glasziou P, Haas M, Plunkett A, Salkeld G. The potential benefits and harms of screening for colorectal cancer. Aust J Public health 1995;19: 24-28.
86. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998;317: 559-65.
87. Heresbach D, Manfredi S, D'Halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006;18: 427-33.
88. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopybased screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 012;9: e1001352.
89. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B.Cochrane Database Syst Rev 2003;2: CD002799.
90. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22: 432-38.
91. Yang B, Zhang B, Xu Y et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123: 357-60.
92. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B.Cochrane Database Syst Rev 2012;9: CD002799.
93. Wang JH, Chang KC, Hung CH, Chen CH, Lu SN. Hepatocellular carcinoma surveillance with 4 versus 12 months interval for patients with chronic viral hepatitis - a randomized community study. Hepatology 2011;54(Suppl 1): 1378A.
94. Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Resp J 1989;2: 656-62.
95. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax 2003;58: 784-89.
96. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M Campbell D. Screening for lung cancer. Cochrane Database Syst Rev 2004;1: CD001991.
97. National Lung Screening Trial Research T, Aberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
98. Brocklehurst P, Kujan O, Glenny AM et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev 2010;11: CD004150.
99. Sankaranarayanan R, Ramadas K, Thomas G et al. Effect of screening on oral cancer mortality in Kerala, India: a clusterrandomised controlled trial. Lancet 2005;365: 1927-33.
100. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107: 882-91.
101. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18: 279-85.
102. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 2006;3: CD004720.
103. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360: 1320-28.
104. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004;46: 717-23; discussion 724.
105. Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-19.
106. Lumen N, Fonteyne V, De Meerleert G et al. Population screening for prostate cancer: an overview of available studies and meta-analysis. Int J Urol 2012;19: 100-08.
107. Djulbegovic M, Beyth RJ, Neuberger MM et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341: c4543.
108. Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst 1990;82: 825-35.
109. Tarini BA. The current revolution in newborn screening: new technology, old controversies. Arch Ped Adolesc Med 2007;161: 767-72.
110. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283: 2975-78.